Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Crane

Showing results (191-200 of 301) with videos related to

Pageof 31
Sort By:
Practical Radiation Oncology|February 29, 2016
Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness MethodKaryn A Goodman, Caroline E Patton, George A Fisher, et al.
BMC Cancer|September 2, 2025
A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)Matthew T McMillan, Marsha Reyngold, Christopher H Crane, et al.
Cancer|October 21, 2017
Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704Yaacov R Lawrence, Jennifer Moughan, Anthony M Magliocco, et al.
Journal of the American College of Surgeons|May 13, 2008
Borderline resectable pancreatic cancer: the importance of this emerging stage of diseaseMatthew H G Katz, Peter W T Pisters, Douglas B Evans, et al.
International Journal of Radiation Oncology, Biology, Physics|August 23, 2001
T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatmentN J Sanfilippo, C H Crane, J Skibber, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2021
Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal CancerLisa A Kachnic, Kathryn A Winter, Robert J Myerson, et al.
Diseases of the Colon and Rectum|September 14, 2022
Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality TherapyJames P Taylor, Iris H Wei, J Joshua Smith, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2006
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysisPrajnan Das, Edward H Lin, Sumita Bhatia, et al.
Acta Oncologica (Stockholm, Sweden)|January 23, 2015
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancerAwalpreet S Chadha, Esengul Kocak-Uzel, Prajnan Das, et al.
Cancer|October 4, 2013
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapyAtin Agarwal, George J Chang, Chung-Yuan Hu, et al.
Pageof 31

Showing results (191-200 of 301) with videos related to

Sort By:
Pageof 31
Practical Radiation Oncology|February 29, 2016
Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness MethodKaryn A Goodman, Caroline E Patton, George A Fisher, et al.
BMC Cancer|September 2, 2025
A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)Matthew T McMillan, Marsha Reyngold, Christopher H Crane, et al.
Cancer|October 21, 2017
Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704Yaacov R Lawrence, Jennifer Moughan, Anthony M Magliocco, et al.
Journal of the American College of Surgeons|May 13, 2008
Borderline resectable pancreatic cancer: the importance of this emerging stage of diseaseMatthew H G Katz, Peter W T Pisters, Douglas B Evans, et al.
International Journal of Radiation Oncology, Biology, Physics|August 23, 2001
T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatmentN J Sanfilippo, C H Crane, J Skibber, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2021
Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal CancerLisa A Kachnic, Kathryn A Winter, Robert J Myerson, et al.
Diseases of the Colon and Rectum|September 14, 2022
Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality TherapyJames P Taylor, Iris H Wei, J Joshua Smith, et al.
International Journal of Radiation Oncology, Biology, Physics|October 24, 2006
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysisPrajnan Das, Edward H Lin, Sumita Bhatia, et al.
Acta Oncologica (Stockholm, Sweden)|January 23, 2015
Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancerAwalpreet S Chadha, Esengul Kocak-Uzel, Prajnan Das, et al.
Cancer|October 4, 2013
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapyAtin Agarwal, George J Chang, Chung-Yuan Hu, et al.
Pageof 31